SCHEDULE 13D/A: DOMA Urges Pacira Sale, Board Overhaul Amid Spending Concerns

Activist investor DOMA Perpetual Capital Management, holding 6.83% of Pacira BioSciences, announced plans to nominate three directors and called for an immediate sale of the company, citing exorbitant executive compensation and general spending.

Summary

• DOMA Perpetual Capital Management LLC and its affiliates (DOMA) beneficially own approximately 6.83% of Pacira BioSciences, Inc.'s outstanding common stock, totaling 2,936,794 shares.
• DOMA intends to nominate three highly-qualified, independent director candidates for election at Pacira's 2026 annual meeting of stockholders.
• DOMA asserts that Pacira's Board of Directors should pursue an immediate sale of the company.
• DOMA considers the current level of executive compensation and general spending at Pacira to be "exorbitant and unmerited."
• DOMA questions whether the Board has exercised appropriate fiduciary oversight regarding company expenditures.
• A preliminary proxy statement and accompanying WHITE proxy card will be filed with the SEC to solicit votes for DOMA's director nominees.
• The John Templeton Foundation, a client of DOMA, beneficially owns 812,019 shares (1.89%) but is not sponsoring the director nominations.

Sentiment

Score: 3

Explanation: The sentiment is negative towards the current management and board of Pacira BioSciences, Inc., as an activist investor is calling for significant changes, including a company sale and board overhaul, due to concerns over executive compensation, spending, and fiduciary oversight. This indicates a strong dissatisfaction with the status quo.

Positives

• Activist investor engagement could lead to enhanced shareholder value through strategic changes or a potential sale.
• The call for an immediate sale could unlock value for shareholders if the company is undervalued.
• Nomination of independent directors could improve corporate governance and oversight.

Negatives

• Current executive compensation and general spending are deemed "exorbitant and unmerited" by the activist investor.
• Concerns raised about the Board's exercise of appropriate fiduciary oversight.
• Potential for a proxy contest could create uncertainty and divert management resources.

Risks

• Risk of continued "exorbitant and unmerited" executive compensation and general spending if current board policies persist.
• Risk of inadequate fiduciary oversight by the current Board of Directors.
• Potential for a prolonged and costly proxy fight if the company resists DOMA's proposals.
• Uncertainty regarding the outcome of a potential sale process or board changes could impact stock price.

Future Outlook

DOMA intends to pursue a proxy contest at the 2026 annual meeting to elect three independent directors and advocates for an immediate sale of Pacira BioSciences, Inc.

Management Comments

• The Reporting Persons (excluding JTF which is not making or sponsoring the director nominations) intend to nominate three highly-qualified, independent director candidates at the Issuer's 2026 annual meeting of stockholders.
• The Reporting Persons further assert the Issuer's Board of Directors should pursue an immediate sale of the Issuer.
• The Reporting Persons consider the current level of Executive Compensation and General Spending to be exorbitant and unmerited and questions whether the Board has exercised appropriate fiduciary oversight.

Industry Context

This activist filing highlights a common trend in the biotechnology and pharmaceutical sectors where investors push for strategic alternatives, such as a sale, or improved corporate governance, especially when they perceive underperformance or excessive executive compensation relative to company results. Such actions often occur in industries with high R&D costs and long development cycles, where unlocking value through M&A can be a quicker path to returns.

Comparison to Industry Standards

• DOMA's assertion that "Executive Compensation and General Spending" are "exorbitant and unmerited" implies a belief that these metrics are out of line with industry best practices or peer companies, or are not justified by Pacira's performance. Without specific numbers or named comparable companies, a direct assessment against global benchmarks is not possible from the filing itself, but the criticism suggests a perceived deviation from acceptable standards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if a sale occurs or if new directors improve governance and performance. Risk of uncertainty and potential stock volatility during a proxy contest.
• Management/Board: Current management and board face pressure and potential replacement.
• Employees: Potential for uncertainty regarding future employment if the company is sold or undergoes significant strategic changes.
• Customers/Suppliers: No direct impact mentioned, but a change in company ownership or strategy could indirectly affect relationships.

Next Steps

• DOMA will file a preliminary proxy statement and accompanying WHITE proxy card with the SEC.
• DOMA intends to solicit votes for its slate of director nominees at Pacira's 2026 annual meeting of stockholders.
• DOMA will identify the individuals to be nominated as director candidates.

Key Dates

Recommendation

While the activist investor's demands for a sale and board changes could unlock significant value, the outcome of a proxy fight and potential sale process is uncertain. The current situation introduces volatility and risk. A "hold" recommendation allows investors to monitor developments without making a premature decision, as the situation could evolve positively or negatively depending on the company's response and market conditions.

Keywords

Pacira BioSciences, PCRX, DOMA Perpetual Capital Management, Activist Investor, Shareholder Activism, Proxy Fight, Director Nomination, Corporate Governance, Company Sale, Executive Compensation, Fiduciary Oversight, Biotechnology, Pharmaceuticals